News | July 09, 2013

Diastolic Dysfunction Can Be Targeted to Lower Congestive Heart Failure Readmissions

Researchers analyzed nearly 2,000 congestive heart failure patients

July 9, 2013 — Researchers have announced the results of a study which shows that among patients readmitted for congestive heart failure (CHF), a high E/e’ (a measure of elevated left ventricle filling pressure via ultrasound) at admission is significantly associated with higher 30-day readmission rates.  Focusing on lowering elevated E/e’ levels will be important to control healthcare costs and to reduce the high rates of morbidity and mortality in this patient population.

“We are happy to report that we now have some clear indicators on who might be at most risk of being readmitted in this patient population,” said Manoj Bhandari, M.D., an investigator on the study.

Bhandari and his colleagues analyzed 1,907 CHF patients using echocardiography to check the predictive nature of various measurements and the E/e’ was found to be independently associated with higher readmission rates.

The study, "High Admission E/e’ Is Independently Associated With Higher 30-day Congestive Heart Failure Readmission Rate," was a poster presentation at the 2013 American Society of Echocardiography (ASE) Annual Scientific Sessions.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now